Immunovant Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Immunovant Inc in the first quarter 2026?
Immunovant Inc recorded a cumulative net loss of $-538 million during 12 months ending in the first quarter 2026, resulting in a negative return on equity (ROE) of -76.47%.

Within the Biotechnology & Pharmaceuticals industry 67 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2026 from 3241 to 3427.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) I. Quarter	(Mar 31 2026) IV. Quarter	(Dec 31 2025) III. Quarter	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter
Y / Y Equity Change	20.84 %	20.52 %	14.52 %	15.73 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-538	-506	-464	-465	-447
Return On Equity (TTM)	-76.47 %	-75.23 %	-73.01 %	-75.76 %	-75.09 %
IMVT's Total Ranking	# 3427	# 3241	# 2698	# 2970	# 3047
Equity (TTM) in Millions	735	853	707	520	609
Seq. Equity Change	-13.75 %	20.52 %	36.12 %	-14.6 %	-13.98 %
Seq. Net Income Change	-	-	-	-	-

Back to IMVT Management Effectiveness >> IMVT's 5 Years Annual ROE >> Compare IMVT ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 68
Sector	# 502
Overall	# 3427

Return On Equity Statistics
High	Average	Low
-0 %	-69.14 %	-237.45 %
		(Mar 31 2020)

IMVT Annual Return On Equity	(Mar 31 2026) 2026	(Mar 31 2025) 2025	(Mar 31 2024) 2024	(Mar 31 2023) 2023	(Mar 31 2022) 2022
Total Equity in Millions	853	707	618	362	470
Y / Y Equity Change	20.52 %	14.52 %	70.42 %	-22.84 %	20.01 %
Net Income in Millions	-506	-414	-259	-211	-157
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-59.3 %	-58.5 %	-41.98 %	-58.2 %	-33.36 %

Back to IMVT Management Effectiveness >> IMVT's 5 Years Annual ROE >> Compare IMVT ROE to its Competitors

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IMVT's' Return on Equity at Yahoo Finance
IMVT's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IMVT's Competitors
Subscribers only: Roe for Immunovant Inc 's Suppliers
Subscribers only: Return On Equity for IMVT's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-08T18:14:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.